A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers

Trial Details

NCT ID
NCT05910827
Phase
PHASE1 / PHASE2
Sponsor
Hummingbird Bioscience
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • HMBD-001
  • Docetaxel
  • Cetuximab
Locations (sample)
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Westmead, New South Wales, Australia|-33.80383,150.98768
  • Brisbane, Queensland, Australia|-27.46794,153.02809
  • Greenslopes, Queensland, Australia|-27.50815,153.04951
  • Adelaide, South Australia, Australia|-34.92866,138.59863

Key Eligibility Criteria

  • Ability to understand and be willing to sign an informed consent form
  • Males and females aged over 18 years (or having reached the age of majority according to local laws if the age of majority is \> 18 years of age)
  • Eastern Cooperative Oncology Group (ECOG) status of 0 to 1
  • Arm B only: Locally advanced or metastatic squamous non-small cell lung cancer for which all available standard of care treatment options have been…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →